On this page
chronic lymphocytic leukemia
Explore " chronic lymphocytic leukemia" with insightful episodes like "Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Chronic Lymphocytic Leukemia", "A Year in Review and a Look to the Future: BTKi in CLL and MCL", "What Clinicians Want to Know About Toxicity Considerations Associated with BTK Inhibitors", "Special Edition — Key Presentations on Chronic Lymphocytic Leukemia and Lymphoma from Recent Major Oncology/Hematology Conferences" and "Special Nursing Edition — What I Tell My Patients About New Treatments and Clinical Trials in Chronic Lymphocytic Leukemia" from podcasts like ""Oncology Today with Dr Neil Love", "CCO Oncology Podcast", "Oncology Today with Dr Neil Love", "Oncology Today with Dr Neil Love" and "Oncology Today with Dr Neil Love"" and more!
Episodes (25)
A Year in Review and a Look to the Future: BTKi in CLL and MCL
In this episode, Ana Marin-Niebla, MD, PhD, and Stephan Stilgenbauer, MD, discuss key trial data on the use of BTK inhibitors in CLL and MCL throughout the past year, how these studies have impacted their practice, and what data they are looking forward to in the near future. The discussion includes analyses of:
- SHINE: First-Line Ibrutinib + Bendamustine/Rituximab Followed by Rituximab Maintenance in Older Patients With MCL
- TRIANGLE: Ibrutinib + Chemoimmunotherapy With or Without ASCT vs Chemoimmunotherapy Followed by ASCT in Younger Patients with Previously Untreated MCL
- ZUMA-2: Brexucabtagene Autoleucel in R/R MCL
- BRUIN: Pirtobrutinib for Previously Treated MCL
- GLOW: Fixed-Duration Ibrutinib + Venetoclax vs Chlorambucil + Obinutuzumab in Previously Untreated CLL
- FLAIR: Ibrutinib + Venetoclax vs FCR in Previously Untreated CLL
- ELEVATE-RR: Acalabrutinib vs Ibrutinib in Previously Treated CLL
- ALPINE: Zanubrutinib vs Ibrutinib in Previously Treated CLL
- BRUIN: Pirtobrutinib for Previously Treated CLL
Presenters:
Ana Marin-Niebla, MD, PhD
Hematology Consultant, Lymphoma Unit
Vall d’Hebron Institute of Oncology, Hematology Department
Hospital Universitario Vall d’Hebron
Barcelona, Spain
Stephan Stilgenbauer, MD
Medical Director Comprehensive Cancer Center Ulm
Head, Early Clinical Trials Unit
Head, Division of CLL Dept. of Internal Medicine III
University Medical Center
Ulm University
Ulm, Germany
Link to full program:
https://bit.ly/3MNaUri
What Clinicians Want to Know About Toxicity Considerations Associated with BTK Inhibitors
Special Edition — Key Presentations on Chronic Lymphocytic Leukemia and Lymphoma from Recent Major Oncology/Hematology Conferences
Special Nursing Edition — What I Tell My Patients About New Treatments and Clinical Trials in Chronic Lymphocytic Leukemia
Key Presentations from the 64th American Society of Hematology (ASH) Annual Meeting: Chronic Lymphocytic Leukemia Edition
New Evidence With BTK Inhibitor Therapy in CLL and MCL From EHA 2022
In this episode, Othman Al-Sawaf, MD, and Lydia Scarfò, MD, discuss key trials presented at EHA 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of:
- GAIA/CLL13: phase III trial of time-limited venetoclax + obinutuzumab ± ibrutinib vs chemoimmunotherapy as first-line therapy for CLL
- FLAIR: randomized, adaptive-design phase III trial with data reported from ibrutinib + venetoclax and ibrutinib arm; includes measurable residual disease–defined therapy duration
- BRUIN: phase I/II study of pirtobrutinib for previously treated CLL (including previous BTK inhibitor)
- SHINE: phase III study of ibrutinib with bendamustine + rituximab and rituximab maintenance in older patients with MCL
Presenters:
Othman Al-Sawaf, MD
Faculty of Medicine
University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne
Düsseldorf, Germany
Visiting Scientist
The Francis Crick Institute
UCL Cancer Institute, University College London
London, United Kingdom
Lydia Scarfò, MD
Laboratory of B-Cell Neoplasia, Division of Experimental Oncology
Strategic Research Program on CLL
Università Vita Salute San Raffaele and IRCCS Ospedale San Raffaele
Milano, Italy
Link to full program:
https://bit.ly/3OQ6634
FDA Issues Safety Warning for Blood Cancer Drug + Long COVID Risk Assessment Tool
In this episode, Ayesha talked about a safety warning issued by the US Food and Drug Administration (FDA) for Secura Bio’s Copiktra (duvelisib), which is a drug used to treat adults with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL). The FDA flagged the drug after evaluating long-term survival data, which showed that the drug was associated with a higher risk of serious side effects and a possibly increased risk of death.
Ayesha also talked about a new nuclear magnetic resonance (NMR)-based molecular research tool for the assessment of the risk of Long COVID, including multi-organ damage and cardiovascular disease risk. The phenomics tool is being developed by Bruker for research purposes and is based on well-characterized metabolic and proteomic biomarkers associated with Long COVID. Hear more about the tool and how it can help patients receive appropriate treatment interventions early for Long COVID.
Read the full articles here:
Copiktra Blood Cancer Drug Gets FDA Warning Due to Increased Risk of Serious Side Effects and Death
Bruker Develops New Tool for Assessing Long COVID Risk
For more life science and medical device content, visit the Xtalks Vitals homepage.
Follow Us on Social Media
Twitter: @Xtalks
Instagram: @Xtalks
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured
Persistent circulating SARS-CoV-2 spike antigen associated with long COVID
ASCO 2022: Advances in CLL/SLL
In this episode, John M. Burke, MD, a leading expert, and Amy Esposito, FNP-C provide expert insights on key data presented at the 2022 ASCO annual conference for CLL/SLL regarding:
- Updated response and safety results after 3 years of follow-up from the phase II CAPTIVATE study of ibrutinib and venetoclax in patients with previously untreated CLL
- Updated response and remission rates after 4 years of follow-up from a phase II trial of obinutuzumab, ibrutinib, and venetoclax in patients with either treatment-naïve or relapsed/refractory CLL
- Progression free survival and safety results after 5 years of follow-up from the ELEVATE-TN phase III study of Acalabrutinib ± Obinutuzumab vs
Obinutuzumab + Chlorambucil as first-line therapy in CLL - Assessments of whether racial and/or ethnic identity, and socioeconomic status are prognostic factors of survival in CLL
Presenter
John M. Burke, MD
Rocky Mountain Cancer Centers
Aurora, Colorado
Moderator
Amy Esposito, FNP-C
Nurse Practitioner
Rocky Mountain Cancer Center
Aurora, Colorado
Expert Answers to Key Questions on Current and Emerging BTK Inhibitor Therapies for CLL and MCL
In this episode, Jeff P. Sharman, MD; Matthew S. Davids, MD, MMSc; and Anthony Mato, MD, MSCE, answer questions from a live CCO webinar on current best practices and emerging strategies in BTK inhibitor therapy for patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), with questions including:
- For patients with CLL, when should acalabrutinib-, ibrutinib-, or venetoclax-based regimens be considered?
- What is the optimal therapy for a patient with del(17p) CLL?
- When should an anti-CD20 antibody be added to BTK inhibitor therapy for patients with CLL?
- What are best practices in the use of BTK inhibitors for patients with MCL?
- How can BTK inhibitor resistance occur?
- How might investigational noncovalent BTK inhibitors be used should they be approved?
- What are key adverse events with BTK inhibitors?
Presenters:
Jeff P. Sharman, MD (chair)
Medical Director
Hematology Research
US Oncology
Willamette Valley Cancer Institute
Eugene, Oregon
Matthew S. Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts
Anthony Mato, MD, MSCE
Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York
Content based on an online CME program supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit https://bit.ly/3wXOsV5.
Link to full program:
https://bit.ly/3NEpsYQ
Recent Advances in the Treatment of Chronic Lymphocytic Leukemia with Dr Peter Hillmen
Updates from the 2021 ASH Meeting on Chronic Lymphocytic Leukemia with Dr Matthew Davids
Chronic Lymphocytic Leukemia with Professor Dr Arnon Kater
Expert Insights on Highlights From ASH 2020 on Lymphomas/CLL
In this episode, Jeremy S. Abramson, MD, MMSc, discusses highlights of the key data from ASH 2020 on the treatment of patients with lymphomas/CLL, with topics including:
- Approved and Investigational Targeted Therapeutics for CLL
- Investigational CAR T-Cell Therapy for Indolent Lymphomas, CLL, and Mantle Cell Lymphoma
- Bispecific Antibodies and Other Investigational Targeted Agents for Lymphomas
- Treatment for Older Patients With Hodgkin Lymphoma
Presenters:
Jeremy S. Abramson, MD, MMSc
Associate Professor
Department of Medicine
Harvard Medical School
Director, Center for Lymphoma
Massachusetts General Hospital
Boston, Massachusetts
Content based on an online CME program supported by educational grants from Amgen; AstraZeneca; Bristol-Myers Squibb; Epizyme, Inc.; GlaxoSmithKline; Incyte Corporation; Janssen Biotech; Karyopharm Therapeutics Inc.; Novartis; PharmaEssentia Corp.; Seattle Genetics; and Takeda Oncology.
Link to full program:
https://bit.ly/3tyQ9nG
Current Role of Minimal Residual Disease Assessment in the Management of Multiple Myeloma and Chronic Lymphocytic Leukemia with Drs Shaji Kumar and Philip Thompson
Key Presentations on Chronic Lymphocytic Leukemia and Follicular Lymphoma from the 2020 ASH Annual Meeting with Dr Ann LaCasce
Front-Line Treatment of Chronic Lymphocytic Leukemia with Dr Steven Coutre
Application of Individualized Treatment for CLL/SLL: Novel Agents, Combinations, and Sequencing Therapy: FAQ
In this episode,William G. Wierda, MD, PhD, Jeremy S. Abramson, MD, MMSc, and Brian Hill, MD, PhD, answer questions focused on personalizing therapy for patients with CLL considering patient characteristics and currently available clinical evidence.
Presenters:
William G. Wierda, MD, PhD, Program Director
Professor of Medicine
Chief, Section of CLL
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas
Jeremy S. Abramson, MD, MMSc
Associate Professor
Department of Medicine
Harvard Medical School
Director, Center for Lymphoma
Massachusetts General Hospital
Boston, Massachusetts
Brian Hill, MD, PhD
Director, Lymphoid Malignancies Program
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio
Content based on an online CME program supported by educational grants from AstraZeneca; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Lilly.
Link to full program, including associated downloadable slidesets:
http://bit.ly/3mLjeIb